SGLT2 inhibitors, when used alone or in combination with metformin, are also associated with reduced risk of hypoglycemia by increasing plasma glucagon concentrations and decreasing plasma insulin concentrations21,22. This evidence concerns the gene INS and Hypoglycemia.